Lithium Carbona in contrast-induced acute kidney injury: a prospective, randomized, controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021798

Enrollment

Unknown

Registered

2019-03-10

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast induced acute kidney injury

Interventions

Experimental group:Intravenous infusion of 0.9% sodium chloride injection at a rate of 1.0 ml/(kg·h) 6 h before and 12 h after contrast injection+ Lithium carbonate sustained release tablets 300mg/600

Control group:Intravenous infusion of 0.9% sodium chloride injection at a rate of 1.0 ml/(kg·h) 6 h before and 12 h after contrast injection+ placebo qd oral for 3 days

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 60 years, Male or female; 2. According to the formula of chronic kidney disease epidemiology collaboration (CKD-EPI), the estimated glomerular filtration rate is greater than or equal to 15ml / min / 1.73m^2; 3. Creatinine increase < 0.3mg/dl (26.5µmol/L) in the preceding 1 month prior to angiography; 4. EF=30%; 5. Contrast agent acute kidney injury risk score =6 points or patients with diabetes before angiography.

Exclusion criteria

Exclusion criteria: 1. Subjects took lithium or related preparations before angiography for any reason; 2. Subjects had a history of persistent sepsis or sepsis in the past 2 weeks and were defined as having the following conditions: T > 38 ° C or 90 beats / min, and breathing > 20 beats / Min, WBC> 12*10^9/L or > 10% polymorphonuclear cells; 3. Known to be allergic to lithium carbonate or any of the above drugs; 4. Subjects with other serious physical or mental illnesses; 5. Pregnant or lactating women; 6. Refusal to sign written informed consent or inability to or unwilling to abide by research protocols approved by the investigator; 7. Subjects considered by the investigator to have any other factors not suitable for participation in the clinical study.

Design outcomes

Primary

Measure	Time frame
Serum creatinine;	—

Secondary

Measure	Time frame
Neutrophil Gelatinase Associated Lipocalin;Kidney Injury Molecule-1;Adverse event;Long-term prognosis;	—

Countries

China

Contacts

Public ContactLiu Zhangsuo

The First Affiliated Hospital of Zhengzhou University

zhangsuoliu@zzu.edu.cn+86 0371 66913084

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026